X4 PHARMACEUTICALS, INC Diluted Shares Outstanding (Weighted Average)
X4 PHARMACEUTICALS, INC (XFOR) reported Diluted Shares Outstanding (Weighted Average) of 126.34 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 126.34M shares, a 1604.36% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 126.29M shares, a 1738.51% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 111.44M shares, a 1551.70% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 43.27M shares, a 546.30% increase year-over-year.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for fiscal 2025 was 42.29M shares, a 531.04% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for fiscal 2024 was 6.70M shares, a 13.08% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for fiscal 2023 was 5.93M shares, a 90.67% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC weighted average number of shares outstanding, diluted for fiscal 2022 was 63.53M shares, a 146.71% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 126.34M shares 10-Q · filed 2026-08-06 | 126.32M shares 10-Q · filed 2026-08-06 | 121.36M shares derived: average of 3 quarters · filed 2026-08-06 | 101.84M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 126.29M shares 10-Q · filed 2026-05-06 | 118.87M shares derived: average of 2 quarters · filed 2026-05-06 | 93.67M shares derived: average of 3 quarters · filed 2026-05-06 | 72.10M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 111.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 77.36M shares derived: average of 2 quarters · filed 2026-03-17 | 54.04M shares derived: average of 3 quarters · filed 2026-08-06 | 42.29M shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 43.27M shares 10-Q · filed 2025-11-05 | 25.34M shares derived: average of 2 quarters · filed 2026-08-06 | 19.24M shares 10-Q · filed 2025-11-05 | 16.08M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 7.41M shares 10-Q · filed 2026-08-06 | 7.10M shares 10-Q · filed 2026-08-06 | 7.01M shares derived: average of 3 quarters · filed 2026-08-06 | 6.93M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | 6.87M shares 10-Q · filed 2026-05-06 | 6.81M shares derived: average of 2 quarters · filed 2026-05-06 | 6.77M shares derived: average of 3 quarters · filed 2026-05-06 | 6.75M shares derived: average of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | 6.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 6.72M shares derived: average of 2 quarters · filed 2026-03-17 | 6.71M shares derived: average of 3 quarters · filed 2026-03-17 | 6.70M shares 10-K · filed 2026-03-17 | 201.06M shares 10-K · filed 2025-03-26 | |||
| 2024-09-30 | 6.70M shares 10-Q · filed 2025-11-05 | 200.87M shares 10-Q · filed 2024-11-13 | 6.69M shares derived: average of 2 quarters · filed 2025-11-05 | 6.69M shares 10-Q · filed 2025-11-05 | 200.61M shares 10-Q · filed 2024-11-13 | -117.12M shares derived: average of 4 quarters · filed 2026-03-17 | ||
| 2024-06-30 | 6.69M shares 10-Q · filed 2025-08-08 | 200.80M shares 10-Q · filed 2024-08-08 | 6.68M shares 10-Q · filed 2025-08-08 | 200.46M shares 10-Q · filed 2024-08-08 | -158.40M shares derived: average of 3 quarters · filed 2026-03-17 | -69.55M shares derived: average of 4 quarters · filed 2026-03-17 | ||
| 2024-03-31 | 6.67M shares 10-Q · filed 2025-05-01 | 199.99M shares 10-Q · filed 2024-05-07 | -240.94M shares derived: average of 2 quarters · filed 2026-03-17 | -94.96M shares derived: average of 3 quarters · filed 2026-03-17 | -29.04M shares derived: average of 4 quarters · filed 2026-03-17 | |||
| 2023-12-31 | -488.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -145.78M shares derived: average of 2 quarters · filed 2026-03-17 | -40.94M shares derived: average of 3 quarters · filed 2026-03-17 | 5.93M shares 10-K · filed 2026-03-17 | 177.81M shares 10-K · filed 2024-03-21 | |||
| 2023-09-30 | 196.99M shares 10-Q · filed 2024-11-13 | 196.99M shares 10-Q · filed 2023-11-09 | 182.86M shares derived: average of 2 quarters · filed 2024-11-13 | 170.75M shares 10-Q · filed 2024-11-13 | 170.75M shares 10-Q · filed 2023-11-09 | 153.22M shares derived: average of 4 quarters · filed 2025-03-26 | ||
| 2023-06-30 | 168.74M shares 10-Q · filed 2024-08-08 | 168.74M shares 10-Q · filed 2023-08-10 | 157.42M shares 10-Q · filed 2024-08-08 | 157.42M shares 10-Q · filed 2023-08-10 | 138.63M shares derived: average of 3 quarters · filed 2025-03-26 | 124.77M shares derived: average of 4 quarters · filed 2025-03-26 | ||
| 2023-03-31 | 145.97M shares 10-Q · filed 2024-05-07 | 145.97M shares 10-Q · filed 2023-05-04 | 123.57M shares derived: average of 2 quarters · filed 2025-03-26 | 110.12M shares derived: average of 3 quarters · filed 2025-03-26 | 91.45M shares derived: average of 4 quarters · filed 2025-03-26 | |||
| 2022-12-31 | 101.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 92.19M shares derived: average of 2 quarters · filed 2025-03-26 | 73.27M shares derived: average of 3 quarters · filed 2025-03-26 | 63.53M shares 10-K · filed 2025-03-26 | 63.53M shares 10-K · filed 2023-03-21 | |||
| 2022-09-30 | 83.21M shares 10-Q · filed 2023-11-09 | 59.32M shares derived: average of 2 quarters · filed 2023-11-09 | 50.98M shares 10-Q · filed 2023-11-09 | 45.34M shares derived: average of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | 35.44M shares 10-Q · filed 2023-08-10 | 34.59M shares 10-Q · filed 2023-08-10 | 32.72M shares derived: average of 3 quarters · filed 2024-03-21 | 31.19M shares derived: average of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | 33.74M shares 10-Q · filed 2023-05-04 | 31.37M shares derived: average of 2 quarters · filed 2024-03-21 | 29.78M shares derived: average of 3 quarters · filed 2024-03-21 | |||||
| 2021-12-31 | 28.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 27.80M shares derived: average of 2 quarters · filed 2024-03-21 | 25.75M shares 10-K · filed 2024-03-21 | 25.75M shares 10-K · filed 2023-03-21 | ||||
| 2021-09-30 | 26.61M shares 10-Q · filed 2022-11-03 | 24.67M shares 10-Q · filed 2022-11-03 | ||||||
| 2020-12-31 | 20.08M shares 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |